| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 02/10/2005 | US20050033018 Receptors and membrane-associated proteins |
| 02/10/2005 | US20050033017 Nucleotide sequences coding receptor for advanced glycation endproducts (RAGE) for identifying modulators for treatment and prevention of cell proliferative and cardiovascular disorders |
| 02/10/2005 | US20050032890 Aniline-derived ligands for the thyroid receptor |
| 02/10/2005 | US20050032874 Indole derivatives |
| 02/10/2005 | US20050032867 Pharmaceutical composition comprising a 5ht1 receptor agonist |
| 02/10/2005 | US20050032865 Cyanomethyl substituted thiazoliums and imidazoliums and treatments of disorders associated with protein aging |
| 02/10/2005 | US20050032863 Method of treating or preventing central nervous system disorders with compounds having selectivity for the alpha 3 subunit of the benzodiazepine receptor |
| 02/10/2005 | US20050032862 Preparing a novel crystal form by sonication and temperature oscillation of a suspension; filtered and dried faster; treating cardiovascular disorders |
| 02/10/2005 | US20050032858 Novel heterocyclic compound and anti-inflamatory agent |
| 02/10/2005 | US20050032852 1-(N-substituted sulfonamido),4-(substituted isooxazoly-4-yl)benzenes, e.g., N-ethyl-4-(5-methyl-3-phenylisoxazol-4-yl)-N-propionylbenzenesulfonamide; side effect reduction; solubility; stability; bioavailability, i.e., readily penetrate membranes; non-steroidal antiinflammatory agents; analgesics |
| 02/10/2005 | US20050032851 E. g.,N-[[4-[2-(5-Methylpyridin-3-yl)-4-(trifluoromethyl)-1H-imidazol-1-yl]phenyl]sulfonyl]acetamide; side effect reduction; non-steroidal antiinflammatory agents; antiarthritic agents; analgesics; antipyretics; acylation of the corresponding sulfoamide by an anhydride a solvent and base |
| 02/10/2005 | US20050032848 Administering enzyme inhibitors of beta secretase, an enzyme responsible for the production of amyloid beta peptide by mediating the cleavage of amyloid precursor proteins; Alzheimer's disease; cognition activators; Down's syndrome; neurodegenerative diseases; other dementias of mixed origins |
| 02/10/2005 | US20050032845 1,1-and 1,2-disubstituted cyclopropane compounds |
| 02/10/2005 | US20050032840 Administering the analgesic, 2-methyl-1-(1-piperidinyl)-(2-thienyl)cyclohexane (gacyclidine), by itself or in conjuction with another analgesic; prevention and/or treating pain and/or nociception; preventing hyperalgias and/or allodynias induced by an analgesic acting on opiate receptors |
| 02/10/2005 | US20050032837 For therapy of irritable bowel syndrome, drug addiction or dependency, including alcohol addiction, depression, anxiety, schizophrenia, anxiety, schizophrenia and eating disorders |
| 02/10/2005 | US20050032830 Ether substituted imidazopyridines |
| 02/10/2005 | US20050032825 rapamaycin derivatives used as fungicides, anticarcinogenic agents, immunosuppressants or as coatings on drug eluting stents to prevent restenosis |
| 02/10/2005 | US20050032823 analgesics; antipyretics; antiinflammatory agents; antiarthritic agents |
| 02/10/2005 | US20050032820 Novel spiro compounds |
| 02/10/2005 | US20050032816 N-oxide anthranylamide derivatives and their use as medicaments |
| 02/10/2005 | US20050032809 5-HT receptor ligands and uses thereof |
| 02/10/2005 | US20050032808 Pyrazine carboxamide compounds for use in treatment of obesity, psychiatric and neurological disorders; for example, N-(1-piperidinyl)-5,6-diphenyl-2-pyrazinecarboxamide |
| 02/10/2005 | US20050032806 Method for treating anhedonia using dopamine agonists |
| 02/10/2005 | US20050032799 Treating a CNS disorder by orally administering to a patient a therapeutically effective amount of lamotrigine or a pharmaceutically acceptable derivative; for treatment of epilepsy, pain, edema, multiple sclerosis, psychological disorders, schizophrenia, bipolar disorders; side effect reduction |
| 02/10/2005 | US20050032792 Peptidyl spiroheterocyclic, amidino and guanidino compounds; reversible inhibitors of the cysteine protease cathepsin S, K, F, L and B; useful in the treatment of autoimmune and other related diseases |
| 02/10/2005 | US20050032791 Derivatives of sulphonamides, their preparation and use as medicaments |
| 02/10/2005 | US20050032786 1, 3-benzothiazinone derivatives and use thereof |
| 02/10/2005 | US20050032779 enzyme inhibitors such as 2-[4-(4-Dimethylaminophenyl)piperazin-1-yl]4,5-dihydroimidazo[4,5,1-ij]quinolin-6-one, used for treating or preventing disorders in which poly/ADP-ribose/ polymerase is involved |
| 02/10/2005 | US20050032772 Compounds useful as reversible inhibitors of cysteine proteases |
| 02/10/2005 | US20050032758 Hormone replacement therapy and depression |
| 02/10/2005 | US20050032746 Arylsulfanyl and heteroarylsulfanyl derivatives for treating pain |
| 02/10/2005 | US20050032724 Multidrug Resistance Protein 1 (MRP1); mutagenesis |
| 02/10/2005 | US20050032723 Methods for increasing in vivo efficacy of oligonucleotides and inhibiting inflammation in mammals |
| 02/10/2005 | US20050032715 Composition and method for treatment of neoplastic diseases associated with elevated matrix metalloproteinase activities using catechin compounds |
| 02/10/2005 | US20050032708 up-regulating glutathione metabolism in the central nervous system by up-regulating levels of glutathione precursors (N-acetyl cysteine); for treating neuropsychiatric disorder like schizophrenia, psychosis, bipolar disorder, manic depression, affective disorder, drug induced psychosis, delirium |
| 02/10/2005 | US20050032702 Medicinal product and method for treatment of conditions affecting neural stem cells or progenitor cells |
| 02/10/2005 | US20050032686 administering to a manimal a therapeutically effective amount of ES-62 ( a glycoprotein) to treat an inflammatory disease: arthritis and chronic obstructive pulmonary disease |
| 02/10/2005 | US20050032682 Contains erythropoietin, which protectively acts on survival of oligodendrocytes, which form myelin sheath, in cerebrovascular dementia typified by multiple sclerosis and Binswanger disease |
| 02/10/2005 | US20050032207 Method for isolating, culturing and differentiating intestinal stem cells for therapeutic use |
| 02/10/2005 | US20050032168 17 human secreted proteins |
| 02/10/2005 | US20050032161 Novel xanthine phosphoribosyl transferase |
| 02/10/2005 | US20050032155 Expression vector comprising nucleotide sequences coding defective receptor protein for use as model in treatment and prevention of convulsive disorders |
| 02/10/2005 | US20050032131 Methods for preventing neural tissue damage and for the treatment of alpha-synuclein diseases |
| 02/10/2005 | US20050031709 Butyrospermum-triterpene fraction containing lupeol; alpha -amyrin and/or beta amyrin, and butyrospermol; plant extract |
| 02/10/2005 | US20050031675 Water soluble polymer such as pullulan and an antimicrobial effective amount of thymol, methyl salicylate, eucalyptol and/or menthol; killing the plaque-producing germs that cause dental plaque, gingivitis and bad breath |
| 02/10/2005 | US20050031674 Cereal beta glucan compositions, methods of preparation and uses thereof |
| 02/10/2005 | US20050031668 biocompatible nonerodible polymeric device which releases dopamine agonist continuously with generally linear release kinetics for extended periods of time; Parkinson's disease; erectile dysfunction and restless leg syndrome |
| 02/10/2005 | US20050031667 Implantable polymeric device for sustained release of dopamine agonist |
| 02/10/2005 | US20050031629 An immunogenic A beta fragment linked to a carrier molecule to form a conjugate, wherein the carrier molecule promotes an immune response comprising antibodies to the A beta fragment; Alzheimer's disease; antibodies |
| 02/10/2005 | US20050031603 Obtainable from whey fraction of milk curd; centrifugation; ultrafiltration; lyophilization |
| 02/10/2005 | US20050031577 Therapeutic polyesters and polyamides |
| 02/10/2005 | US20050029705 Extrusion die |
| 02/10/2005 | CA2534464A1 Benzoxazepine compound |
| 02/10/2005 | CA2534460A1 Benzylamine derivative |
| 02/10/2005 | CA2534374A1 Effects of sporoderm-broken germination activated ganoderma spores on treatment of spinal cord injury and proliferation and/or differentiation of neural stem cells in injured spinal cord |
| 02/10/2005 | CA2534295A1 2-methoxymethyl-3-(3,4-dichlorophenyl)-8-azabicyclo[3.2.1]octane tartrate salts |
| 02/10/2005 | CA2533499A1 Inhalable gaseous medicine based on xenon and nitrous oxide |
| 02/10/2005 | CA2533475A1 Neuroprotective benzo[1,3]oxathol-2-ones |
| 02/10/2005 | CA2532965A1 3, 4-disubstituted 1h-pyrazole compounds and their use as cyclin dependent kinases (cdk) and glycogen synthase kinase-3 (gsk-3) modulators |
| 02/10/2005 | CA2532382A1 N-sulfonylheterocyclopyrrolylalkylamine compounds as 5-hydroxytryptamine-6 ligands |
| 02/10/2005 | CA2531333A1 Triazolopyrimidine derivatives as glycogen synthase kinase 3 inhibitors |
| 02/10/2005 | CA2531320A1 Reversibly immortalised olfactory ensheathing glia and their use to promote neuronal regeneration |
| 02/09/2005 | EP1505148A1 Methods of screening for agonistic antibodies |
| 02/09/2005 | EP1505063A1 Benzimidazole derivatives |
| 02/09/2005 | EP1504762A1 Medicine for prevention of and treatment for amyloidosis |
| 02/09/2005 | EP1504758A2 Controlled-release formulations coated with aqueous dispersions of ethylcellulose |
| 02/09/2005 | EP1504757A2 Controlled-release formulations coated with aqueous dispersions of ethylcellulose |
| 02/09/2005 | EP1504756A1 Medicament compositions comprising a heterocyclic compound and an anticholinergic |
| 02/09/2005 | EP1504124A1 Ldl receptor-related proteins 1 and 2 and treatment of bone or cartilage conditions |
| 02/09/2005 | EP1504118A2 Therapeutic use of selective pde10 inhibitors |
| 02/09/2005 | EP1504007A1 Imidazo-triazine derivatives as ligands for gaba receptors |
| 02/09/2005 | EP1503998A1 Heteroaryl substituted spirocyclic sufamides for inhibition of gamma secretase |
| 02/09/2005 | EP1503991A1 Hexahydro-pyridazine-3-carboxylic acid derivatives, pharmaceutical compositions containing same and preparation methods thereof |
| 02/09/2005 | EP1503990A1 Active substances for the treatment, diagnosis and prophylaxis of diseases in which abnormal protein structures occur |
| 02/09/2005 | EP1503989A1 Dopamine receptor modulators as antipsychotic agents |
| 02/09/2005 | EP1503988A2 Fredericamycin derivatives |
| 02/09/2005 | EP1503801A2 Non-invasive delivery of polypeptides through the blood-brain barrier, and in vivo selection of endocytotic ligands |
| 02/09/2005 | EP1503795A2 Use of heat shock proteins to enhance efficacy of antibody therapeutics |
| 02/09/2005 | EP1503794A1 Methods of treatement using ctla-4 antibodies |
| 02/09/2005 | EP1503790A1 Intracranial treatment of neuropsychiatric disorders by clostridial neurotoxins such as botulinum toxin |
| 02/09/2005 | EP1503788A2 Treatment of alpha-galactosidase a deficiency |
| 02/09/2005 | EP1503779A2 Methods for slowing senescence and treating and preventing diseases associated with senescence |
| 02/09/2005 | EP1503778A2 Formulation of a mixture of free-b-ring flavonoids and flavans as a therapeutic agent |
| 02/09/2005 | EP1503777A1 7-hydroxy chromones as potent antioxidants |
| 02/09/2005 | EP1503773A1 Hepatoprotective activity of 2 -p-hydroxybenzoylmussaenosidic acid |
| 02/09/2005 | EP1503771A1 Sedative materials and treatments |
| 02/09/2005 | EP1503767A2 Compositions and methods for treatment of vitamin d deficiency |
| 02/09/2005 | EP1503765A2 Use of modulators of nicotinic receptors for treatment of cognitive dysfunction |
| 02/09/2005 | EP1503759A2 Substituted quinolone carboxylic acids, their derivatives, site of action, and uses thereof |
| 02/09/2005 | EP1503749A2 Methionine aminopeptidase-2 inhibitors and methods of use thereof |
| 02/09/2005 | EP1503748A1 Drugs for mitigating taxane-induced neurotoxicity |
| 02/09/2005 | EP1503745A2 15625 receptor, a novel g-protein coupled receptor |
| 02/09/2005 | EP1503740A1 Monocompartment osmotic controlled drug delivery system |
| 02/09/2005 | EP1430047B1 Substituted alkylaminopyridazinone derivatives, process for the preparation thereof and pharmaceutical composition containing the same |
| 02/09/2005 | EP1430034B1 Substituted alkylaminopyridazinone derivatives, process for the preparation thereof and pharmaceutical composition containing the same |
| 02/09/2005 | EP1423132A4 Complex mixtures exhibiting selective inhibition of cyclooxygenase-2 |
| 02/09/2005 | EP1414816B1 Stable polymorph of flibanserin, technical process for its preparation and the use thereof for preparing medicaments |
| 02/09/2005 | EP1370268A4 Methods for treating stress disorders using glucocorticoid receptor-specific antagonists |
| 02/09/2005 | EP1349839B1 Phenylethenyl or phenylethinyl derivatives as glutamate receptor antagonists |
| 02/09/2005 | EP1339717B1 Novel carbamate-substituted pyrazolopyridine derivatives |